Congressional investigation into Alzheimer’s drug Aduhelm objects to FDA and Biogen
Anthony Fauci is preparing to retire after half a century in government
December 29, 2022
What’s next for COVID? Here’s what you should know
December 29, 2022 [ad_1]
The report said the FDA’s approval process for Aduhelm was “riddled with irregularities” and criticized Biogen for setting an “unjustifiably high price.”
[ad_2]
Source link
